Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592069 | 1.00 | PTGS1 (0.41) | PTGS1SLC7A11LMNAKDM4EDUSP3 | |
| SCHEMBL8630034 | 1.00 | PTGS1 (0.41) | PTGS1SLC7A11LMNAKDM4EDUSP3 | |
| SCHEMBL5712805 | 0.85 | LMNA (0.43) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4617318 | 0.83 | PTGS1 (0.38) | PTGS1SLC7A11LMNAKDM4EDUSP3 | |
| SCHEMBL8941525 | 0.80 | LMNA (0.40) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL15392088 | 0.80 | LMNA (0.47) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4862805 | 0.79 | USP2 (0.44) | PTGS1SLC7A11LMNAKDM4E | |
| SCHEMBL9223741 | 0.79 | USP2 (0.44) | PTGS1SLC7A11LMNAKDM4E | |
| SCHEMBL3031860 | 0.79 | LMNA (0.44) | PTGS1SLC7A11LMNAKDM4EDUSP3 | |
| SCHEMBL1824408 | 0.78 | KDM4E (0.39) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728289-B1 | OPTIMISED COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2025-09-10 | — | — | EP | disclosed |
| US-20250066416-A1 | OPTIMISED COMPOUNDS | THE UNIVERSITY OF MELBOURNE (AU) | 2025-02-27 | — | — | US | disclosed |
| US-12195557-B2 | Optimised compounds | Axelia Oncology Pty Ltd (AU) | 2025-01-14 | — | — | US | disclosed |
| CN-118161614-A | Treatment of respiratory tract infections with TLR2 agonists | 艾娜呼吸私人有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3600374-B1 | TREATMENT OF RESPIRATORY INFECTION | Ena Respiratory Pty Ltd (AU) | 2024-05-15 | — | — | EP | disclosed |
| CN-110461351-B | Treatment of respiratory tract infections with TLR2 agonists | 艾娜呼吸私人有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20210230217-A1 | OPTIMISED COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2021-07-29 | — | — | US | disclosed |
| US-20210177795-A1 | ADMINISTERING COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2021-06-17 | — | — | US | disclosed |
| EP-3727372-A1 | ADMINISTRATION OF A TLR2 AGONIST FOR THE TREATMENT OR PREVENTION OF A RESPIRATORY CONDITION ASSOCIATED WITH AN INFECTIOUS AGENT | Ena Therapeutics Pty Ltd (AU) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728289-A1 | OPTIMISED COMPOUNDS | Ena Therapeutics Pty Ltd (AU) | 2020-10-28 | — | — | EP | disclosed |
| WO-2018176099-A1 | TREATMENT OF RESPIRATORY INFECTION WITH A TLR2 AGONIST | Ena Therapeutics Pty Ltd (AU) | 2018-10-04 | — | — | WO | disclosed |
| US-9340622-B2 | Synthetic immunogen useful for generating long lasting immunity and protection against pathogens | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-17 | — | — | US | disclosed |
| EP-2616098-B1 | A SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS | COUNCIL SCIENT IND RES (IN) | 2016-04-20 | — | — | EP | disclosed |
| CN-103402539-B | A kind of for generation of the lasting immunity of enantiopathy substance and the synthetic immunogen of protection | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-02-24 | — | — | CN | disclosed |
| CN-103402539-A | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens | COUNCIL SCIENT IND RES | 2013-11-20 | — | — | CN | disclosed |
| US-8569823-B2 | Semiconductor device and manufacturing method thereof | KABUSHIKI KAISHA TOSHIBA (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2616098-A2 | A SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS | Council of Scientific & Industrial Research (IN) | 2013-07-24 | — | — | EP | disclosed |
| US-20130183377-A1 | SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS | UNIVERSITY OF MELBOURNE (AU) | 2013-07-18 | — | — | US | disclosed |
| US-20120068250-A1 | SEMICONDUCTOR DEVICE AND MANUFACTURING METHOD THEREOF | TOSHIBA MEMORY CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035558-A2 | A SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230217-A1 | OPTIMISED COMPOUNDS | TLR2, TLR3, TLR1 | PTGS1 1521/4885SLC7A11 3810/4885LMNA 3226/4885 |
| US-20250066416-A1 | OPTIMISED COMPOUNDS | TLR2, TLR3, TLR1 | PTGS1 1521/4885SLC7A11 3810/4885LMNA 3226/4885 |
| US-12195557-B2 | Optimised compounds | TLR2, TLR3, TLR1 | PTGS1 1521/4885SLC7A11 3810/4885LMNA 3226/4885 |
| US-20130183377-A1 | SYNTHETIC IMMUNOGEN USEFUL FOR GENERATING LONG LASTING IMMUNITY AND PROTECTION AGAINST PATHOGENS | CD4, TLR2, CD74 | PTGS1 1222/4885SLC7A11 961/4885LMNA 1833/4885 |
| US-20210177795-A1 | ADMINISTERING COMPOUNDS | TLR2, TLR3, TLR5 | PTGS1 491/4885SLC7A11 3217/4885LMNA 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.